ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

A RESEARCH STUDY TO ASSESS THE ALPHA-INTERFERON EFFECTIVENESS AMONG MALES SUFFERING FROM HEPATITIS C (HCV)

Dr Saba Khalid, Dr Arshia Ahmad, Dr Nazish Tanveer, Dr. Shabeeh e Zahra

Background: For the treatment of chronic hepatitis C, chemotherapy with different drugs is used a-interferon is one of these drugs. Objectives: The objective of this study was to determine the efficiency of a-interferon in males diagnosed with Hepatitis C. Patients and Methods: This research was completed in the timeframe of February to August 2018 at Jinnah Hospital, Lahore. Total patients were selected for study were 20 males diagnosed with Hepatitis C. The age bracket for these patients was between 24 – 51 years of age. The selected patients were provided with an injection of a-interferon three times a week. After execution of 6 months of chemotherapy, their sera were assessed. Results: The number of patients who became negative for HCV after six months of management with a-interferon was 18 (90%). The levels of serum total bilirubin before and after management with a-interferon were (0.939 ± 0.07) mg/dl and (0.924 ± 0.09) mg/dl respectively which were normal. The outcomes noticed for serum direct and indirect bilirubin were identical. Before treatment, there observed elevated levels of serum Glutamate Pyruvate Transaminase (SGPT) (337.40 ± 75.38) U/I and after management with a-interferon, these levels became normal (26.8 ± 7.42) U/I before and after management with a-interferon, the levels of alkaline phosphatase (ALP) were normal in patients of our study. Conclusion: Virologic and biochemical reactions can be maintained by a-interferon therapy in patients of chronic hepatitis C. Similar to other nations of the world, it is very advantageous for management of SGPT values within a normal range in patients of Hepatitis C. Keywords: Virologic, Alkaline Phosphatase (ALP), Biochemical, a-Interferon, Chronic, Hepatitis C and Bilirubin.

FULL TEXT